MyoGene Bio is a biotech startup on a mission to develop life-saving therapies for muscle diseases. Our



lead program is a gene editing therapy for Duchenne muscular dystrophy, a rare fatal muscle wasting disease. This therapy uses molecular scissors to permanently remove patient mutations in their own DNA to restore the protein otherwise lacking. MyoGene won second place in Startup302's Life Science category in April 2023. We used the grant money for expenses that weren't able to be covered by our other nondilutive funding including office supplies, a license maintenance fee, travel to investor meetings, and patent costs. This funding was critical to support our intellectual property and license agreement, which is the basis for our therapy, and meeting with investors to support future fundraising. MyoGene is currently in preclinical development where we have shown efficacy of our gene editing therapy in Duchenne models and we are on track to advance to the clinic as

quickly as possible. MyoGene recently got fourth place in the Entrepreneurship World Cup and received Orphan Drug and Rare Pediatric Disease Designations from FDA. The Startup302 award was great recognition, pitch practice, and valuable funding for supporting MyoGene's ongoing efforts to develop a novel therapy for this devastating muscle disease.